Defining the Future of the Stem Cell Industry from Stem Cell Industry Experts, 2017

DUBLIN, September 28, 2017 /PRNewswire/ --

The "Defining the Future of the Stem Cell Industry - Interviews with Stem Cell Industry Executives" report has been added to Research and Markets' offering.

Stem cell research has been in process for over five decades. Stem cells have a unique ability to divide and replicate repeatedly, as well as an unspecialized nature that allows them to differentiate into a wide variety of specialized cell types. In a developing embryo, stem cells can differentiate into all of the embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Several broad categories of stem cells exist, including:

• Embryonic stem cells, derived from blastocysts
• Perinatal stem cells, obtained during the period immediately before and after birth
• Adult stem cells, found in adult tissues
• Induced pluripotent stem cells (iPS cells), produced by genetically reprogramming adults cells
• Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells as research tools, to utilization in cell therapies and integration into 3D printed tissues and organs. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to the pharmaceutical industry.

Rapid Technological Innovation

As a result of this technological innovation, the stem cell industry is undergoing rapid change. As of July 2017, a search for stem cells yields the following results:

• 5,932 Clinical Trials - Search conducted via ClinicalTrials.gov, a global registry of clinical trials that contains approximately 3/4th of trials worldwide, using the terms stem cell or stem cells
• 45,283 Patents - Search performed using the United State Patent and Trademark Office website, USPTO.gov, using the terms stem cell or stem cells
• 296,399 Scientific Papers - Search performed on PubMed.gov, a global database of scientific publications maintained by the NIH, using the terms stem cell or stem cells
• Google Trends identifies that stem cell terms are widely searched in countries worldwide, led by by Singapore, China, UK, USA, and Australia - Google Trends is a service of Google Inc. that identifies how frequently a particular search term is entered relative to total search volume worldwide

Undoubtedly, there is enormous interest surrounding the stem cell industry. However, this rapid technological changes leaves all industry participants wondering, what will be the future directions for the stem cell industry over the next 5, 10, or 15 years?

Key Topics Covered:

• Abstract
• Interview with Kaz Hirao, CEO of CDI, a FUJIFILM Company - Industrial Scale Production of iPSCs and Differentiated Cells
• Interview with Dr. Yael Margolin, CEO of Gamida Cell - Solving the Unmet Need inHematopoietic Stem Cell Transplantation (HSCT)
• Interview with Dr. Frida Grynspan, VP of R&D for Stem Cell Medicine Ltd. - DevelopingGenetically Modified Muscle Progenitor Cells
• Interview with Dr. Itzchak Angel, CEO of Accellta - Mass Production of Pluripotent Stem Cells 25
• Interview with Eran Cohen, Intellectual Property (IP) Officer for Accellta - Small Company with the IP of a Big Company
• Interview with Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies - The Link Between Nave Stem Cells and Cancer
• Interview with Matthew Feshbach, Founder of Okyanos Cell Therapy (Part 1) - Adipose-Derived Stem Cell Therapies
• Interview with Matthew Feshbach, Founder of Okyanos (Part 2) - Setting the Standard in Adipose-Derived Stem Cell Applications
• Interview with Dr. Bruce Werber, COO of BPSR and CEO of Anu Life Sciences - Regenerative Applications of Placental Tissue Allografts
• Interview with Dr. Ornella Parolini of IPLASS - Understanding Placental Stem Cell Applications
• Interview with Pamela Levin of Tisch MS Research Center of NY - Beginning a Phase II Stem Cell Trial for MS
• Interview with Dr. Saud Sadiq, Director of Tisch MS Research Center of NY - Stem Cells for Reversal of Multiple Sclerosis (MS)
• Interview with James Alexis Mendez, CFO of CryoHoldco - Cord Blood Banking within Latin America
• Interview with Kenneth Harris, Chief Advisor for CuraSense - Growth Rates & Trends within the Cord Blood Industry
• Interview with Joseph Krieger of Boston Biolife - Educating Physicians about Regenerative Medicine
• Interview with ORIG3N's James Lovgren - Creating World's Largest Blood Cell Repository for iPSC Production
• Interview with Tony Veverka, Chief Group Executive of BioEden - How Dental Stem Cells Will Impact Our Future
• Interview with Joo Andrade, CEO of WideCells Group - Unlocking the Future of Cord Blood Banking
• Interview with Dr. Jon Rowley, Founder & CTO of RoosterBio - Radically Changing the Use of Stem Cells
• Interview with Dr. Jon Rowley, Founder & CTO of RoosterBio - Year of the Rooster
• Interview with Dr. Paul Wotton, Board Member of Cynata Therapeutics and Previous CEO of Ocata Therapeutics - Mass Production of Therapeutic Grade MSCs
• Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories - Future of Regenerative Medicine
• Interview with Dr. Denver Lough, President and CEO of PolarityTE - Creating Functionally Polarized Tissue
• Interview with Yaky Yanay, President and Co-CEO of Pluristem Therapeutics - Commercializing Placental Stem Cell Therapeutics
• Interview with Dr. Priya Baraniak of RoosterBio - RM Industry's First Xeno-free (XF) hMSC Cell Banks
• Interview with Dr. Chris Centeno, CEO of Regenexx - Orthopedic Applications of MSCs
• Interview with Dr. Chris Centeno, CEO of Regenexx - Visionary Behind Orthopedic Stem Cell Technology
• Interview with Dr. Askenase of Yale University School of Medicine - MSC-Derived Exosomes for Spinal Cord Repair
• Interview with Robin Smith, CEO of ORIG3N - Creating Patient-Specific iPSCs and a Living Database of Humanity

For more information about this report visit https://www.researchandmarkets.com/research/rlpnrg/defining_the

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com